• Neo Financial

  Participated · Equity · Feb 2026

  Neo Financial builds consumer financial products including a suite of credit cards, Everyday Accounts, Neo Savings, Neo Invest, and Neo Mortgage, and operates Neo for Partners which powers financial solutions for over 10,000 partners. The company serves more than one million customers and offers one of Canada’s lowest mortgage rates. Founded in 2019, Neo is headquartered in Calgary, Winnipeg, and Toronto and has raised more than $650 million in funding. It has been recognized as Canada's top-growing company by The Globe and Mail and placed #1 on the Deloitte Technology Fast 50 for three consecutive years. Neo recently completed a $150 million inaugural credit card securitization to access institutional capital and support growth of its credit card portfolio.

• CardioDx

  Led · Equity · Dec 2014

  CardioDx is a molecular diagnostics firm focused on cardiovascular genomics and the commercialization of Corus CAD, a clinically validated blood test that combines age, sex and gene expression to assess the likelihood of obstructive coronary artery disease in symptomatic patients. The company announced it will use the new funds to broaden commercial use of Corus CAD and to augment research efforts to develop additional genomic tests for coronary artery disease. CardioDx processes all Corus CAD test samples at its CLIA-certified and CAP-accredited clinical laboratory in Redwood City, California. Management cited the milestone of receiving over 100,000 Corus CAD test results as evidence of clinical adoption. Corus CAD has been clinically validated in multiple studies, including PREDICT and COMPASS, and in COMPASS demonstrated higher sensitivity and negative predictive value versus myocardial perfusion imaging. The test and company have received recognition including a Wall Street Journal Technology Innovation Award, a Gold Edison Award, and inclusion in TIME's Top 10 Medical Breakthroughs. CardioDx develops genomic diagnostics for cardiovascular disease, with its core product Corus CAD—a clinically validated, sex-specific gene expression test that measures RNA levels of 23 genes. Corus CAD is commercially available in the U.S. via a patient sample kit processed at the company’s CLIA-certified Palo Alto laboratory. The company said proceeds from the financing will support commercial expansion of Corus CAD, broaden reimbursement coverage, expand its U.S. sales force, and fund continued R&D to develop additional cardiovascular genomic diagnostics. CardioDx highlighted a favorable Medicare coverage decision from Palmetto GBA, making Corus CAD a covered benefit for more than 40 million Medicare enrollees. The company cites clinical validation in multiple prospective trials (PREDICT, COMPASS, IMPACT) and prior studies showing unmet need in noninvasive risk stratification for obstructive coronary artery disease. CardioDx develops blood-based genomic diagnostics for cardiovascular disease, centered on Corus CAD, a clinically validated gene-expression test for obstructive coronary artery disease. Corus CAD measures RNA levels of 23 genes and is the first sex-specific blood test for obstructive coronary artery disease. The test is commercially available in the United States via a patient sample kit and is processed at CardioDx’s CLIA-certified Palo Alto laboratory. Corus CAD has been used to assess more than 13,000 patients and was validated in the PREDICT study published in the Annals of Internal Medicine. The company plans to use new funding to expand reimbursement coverage in the U.S. and to continue development of additional cardiovascular genomic products. CardioDx positions Corus CAD as a decision-making tool to help clinicians avoid unnecessary procedures and radiation exposure. CardioDx develops genomic tests to aid in the assessment and tailoring of care for individuals with cardiovascular diseases such as coronary artery disease, cardiac arrhythmias and heart failure. Its initial product, Corus CAD, is a clinically validated non-invasive genomic blood test that uses gene expression levels and other patient characteristics to quantify the likelihood of obstructive coronary artery disease. The company is funded by investors including Kleiner, Perkins, Caufield & Byers, TPG Biotech, Mohr Davidow Ventures, Intel Capital and Pappas Ventures. CardioDx has raised $5M as part of a Series D round from the GE Healthymagination Fund. The new capital will be used to advance and co-develop diagnostic technologies to improve the care and management of patients with cardiovascular disease.

• Alta Devices

  Participated · Equity · Mar 2011

  Alta Devices, founded in 2007 and based in Santa Clara, CA, focuses on high-efficiency solar PV technologies with an emphasis on lowering production costs. Its core technical work targets advanced materials—particularly thin gallium arsenide layers—and manufacturing and form-factor innovations to raise solar conversion efficiency. The company reports lab progress on techniques such as epitaxial lift off to enable efficient use of very thin GaAs layers. Alta’s technologists are addressing efficient raw-material use, improved manufacturing processes, and new ways to optimize conversion efficiency for energy applications. Alta is currently a development-stage company and has raised funding to move toward commercialization; total investment in the current round to date is $72 million. Strong VC and industry investor participation and board involvement aim to support scale-up and commercialization efforts.

No current team members are available.